GI Surgery – Esophagus | Links Medicus Content Curation & Alerts in Medicine

RCT: Effect of Camrelizumab vs. placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma.

15 Sep, 2021 | 08:51h | UTC

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge – JAMA Oncology (free for a limited period)

Commentary on Twitter

Among patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of camrelizumab to chemotherapy, compared with placebo and chemotherapy, significantly improved overall survival and progression-free survival https://t.co/DAlhmtgvv1

— JAMA (@JAMA_current) September 14, 2021

SAGES guidelines for the surgical treatment of gastroesophageal reflux.

21 Jul, 2021 | 10:34h | UTC

SAGES guidelines for the surgical treatment of gastroesophageal reflux (GERD) – Surgical Endoscopy

Global burden of cancer attributable to alcohol consumption – “Globally, an estimated 741.300, or 4·1% of all new cases of cancer in 2020 were attributable to alcohol consumption”.

14 Jul, 2021 | 11:07h | UTC

Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study – The Lancet Oncology

News release: Alcohol consumption linked to more than 740,000 new cancer cases in 2020 – The Lancet

Commentaries: Alcohol caused 740,000 cancer cases globally last year – study – The Guardian AND Expert reaction to study of alcohol and cancer – Science Media Centre

RCT: Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma.

13 Jul, 2021 | 09:20h | UTC

Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC₅₀10 Randomized Clinical Trial – JAMA Surgery

Commentary: Neoadjuvant chemoradiotherapy plus surgery increases overall survival of patients with advanced esophageal squamous cell carcinoma compared to surgery alone – 2 Minute Medicine

Commentary on Twitter

Long-term outcomes from the NEOCRTEC5010 demonstrated the survival benefit of neoadjuvant chemoradiotherapy followed by surgery compared with surgery alone for patients with locally advanced esophageal squamous cell carcinoma https://t.co/UBBEEAynsy

— JAMA Surgery (@JAMASurgery) June 29, 2021

Ranitidine absolved? FDA study finds Ranitidine does not convert to carcinogen NDMA, regardless of diet.

12 Jul, 2021 | 01:36h | UTC

Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial – JAMA

Editorial: Ranitidine and Risk of N-Nitrosodimethylamine (NDMA) Formation

Commentary: Ranitidine: FDA finds no evidence of elevated NDMA, regardless of diet

Commentaries on Twitter

Despite ranitidine (zantac) being pulled from market last year, a new study from the FDA did not find evidence that it increases concentrations of the carcinogenic metabolite people were worried about (i.e., it's probably safe). From @JAMA_current https://t.co/AdRic2GdXS

— Zack Williams (@QuantPsychiatry) June 28, 2021

In this crossover, randomized clinical trial, oral ranitidine did not significantly increase 24-hour urinary excretion of NDMA when administered with a noncured-meats diet or a cured-meats diet. https://t.co/EszRvfJOFJ

— JAMA (@JAMA_current) June 28, 2021

RCT: Reduced-intensity chemotherapy among older and frail patients with advanced gastroesophageal cancer provides an improved patient experience with no significant detriment in cancer control.

20 May, 2021 | 08:18h | UTC

Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial – JAMA Oncology

Commentary: Lowering Chemo Dose Achieved Happier Patients, Good Outcomes in Elderly GI Cancer Patients – Physician’s Weekly

Commentary on Twitter

The GO2 trial tested reduced intensity of chemo for pts w adv gastroesophageal cancer & found reducing intensity led to comparable survival but w improved patient experience, & decision-making can be enhanced using geriatric assessment https://t.co/DtZOXcozo7 #GeriOnc

— JAMA Oncology (@JAMAOnc) May 13, 2021

Randomized trial long-term results confirm the benefits of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer

20 May, 2021 | 08:16h | UTC

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial – Journal of Clinical Oncology

Commentaries on Twitter

Out at @ASCO_pubs
🔟yr Outcome of Neoadj #Chemoradiotherapy➕Surgery for #EsophagealCancer

☑️Show OS benefit in locally advanced resectable esophageal or junctional #Cancer who receive preop chemorad🧪☢️ According to CROSS, persists at least🔟years‼️https://t.co/yJSibSveAh pic.twitter.com/UssnzuFiEe

— Gil Morgan (@weoncologists) May 14, 2021

Survival benefit of preoperative chemoradiotherapy for patients with esophageal cancer persists – 10-year outcome of the CROSS trial https://t.co/s02sMVpYhI #esocsm #JCO @ErasmusMC @bmeyck pic.twitter.com/2JwV0iOvoB

— ASCO Publications (@ASCO_pubs) May 5, 2021

RCT: Among patients with esophageal cancer, intrathoracic anastomosis after totally or hybrid minimally invasive esophagectomy resulted in lower anastomotic leakage rates and better outcomes when compared with cervical anastomosis.

18 May, 2021 | 07:21h | UTC

Intrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)

Invited commentary: Does the Location Matter for the Anastomosis for Minimally Invasive Esophagectomy? (free for a limited period)

Commentary on Twitter

Intrathoracic anastomosis after MIE is associated with a lower anastomotic leakage rate and better outcome for patients with mid to distal esophageal or gastro-esophageal junction cancer: results of the ICAN trial https://t.co/CXv2CeCnuX pic.twitter.com/QCYg4UJeyF

— JAMA Surgery (@JAMASurgery) May 12, 2021